Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Sets Interim Nitrosamine Limit for Atomoxetine, 5 Generic Makers Launch Fresh Recalls
Japan’s Ministry of Health, Labor and Welfare (MHLW) has set a temporary “interim control limit” for nitrosamine impurities in the ADHD treatment atomoxetine to ensure a stable supply of the drug, while five manufacturers have launched voluntary recalls after detecting…
To read the full story
Related Article
- Towa Lifts Atomoxetine Shipment Curbs Across All Strengths
December 17, 2025
- MHLW Revises Q&A on Nitrosamine Self-Inspections, OKs Use of Interim Control Limit
June 5, 2025
- Strattera Stock Expected to Run Out as Lilly's Talks with Regulators Drag On
March 24, 2025
- Strattera and All Generic Versions Now under Supply Restrictions in Japan
December 17, 2024
- All Versions of Lilly’s Strattera under Restricted Supplies in Japan
November 26, 2024
- Shipment Curbs Growing for Strattera Generics amid Nitrosamine Issues
November 18, 2024
- Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities
November 14, 2024
- Sawai Joins List of Atomoxetine Recalls after Establishing Test Model
September 27, 2024
- 3 More Generic Firms Start Voluntary Recalls of Atomoxetine Products
September 20, 2024
- Don’t Stop Taking Atomoxetine at Own Discretion: MHLW to Patients
September 4, 2024
- MHLW to Set AI Limit for Atomoxetine’s Nitrosamine Impurities at 100 ng/Day
September 2, 2024
REGULATORY
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
- Middle East War Hitting API Air Freight, Trade Group Warns
April 13, 2026
- Japan’s 19th Pharmacopoeia Revision Takes Effect
April 13, 2026
- Voranigo and More Meds Missing from April Listing Slate; Servier Plans Packaging Change
April 10, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…